Who
James Patrick Kelly
EVP, CFO and Treasurer
Company insider
Files Form 4 as: EVP, CFO and Treasurer, Novavax; Executive Vice-President & CFO, Supernus Pharmaceuticals; EVP & Chief Financial Officer, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 144
- Buys
- 1
- Sells
- 14
- Bought
- $30K
- Sold
- $1.4M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 13 Dec 2010
- Last trade
- 7 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Mar 2026filed 9 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —12,223 at $0.00 | filing |
| 7 Mar 2026filed 9 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $59K5,904 at $9.98 | filing |
| 7 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,223 at $0.00 | filing |
| 7 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,223 at $0.00 | filing |
| 7 Mar 2026filed 9 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —12,223 at $0.00 | filing |
| 7 Mar 2026filed 9 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $59K5,904 at $9.98 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —43,167 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $198K20,850 at $9.49 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —43,167 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —43,167 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —43,167 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $198K20,850 at $9.49 | filing |
| 2 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —194,000 at $0.00 | filing |
| 2 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —194,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.8M194,000 at $9.09 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.8M194,000 at $9.09 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —58,666 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $288K28,366 at $10.14 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name James Patrick Kelly; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.